June 30, 2017

Bayer expects negative earnings impact from its Brazilian Crop Science business

Leverkusen, June 30, 2017 - Despite an encouraging start to the year and
continued good growth momentum, Bayer's Crop Science Division will have to
adjust its business forecast for fiscal 2017. At the end of the harvest season
in Brazil, regular stocktaking revealed an unexpectedly high channel inventory
level of crop protection products. For this reason, Bayer will be working with
its customers to initiate measures aimed at normalizing the situation. This
will have a one-time effect of EUR 300 million to EUR 400 million on earnings
(EBITDA before special items) for the full year 2017. Appropriate accounting
measures are already being taken in the second quarter.

Bayer is also expecting earnings to be additionally impacted by unfavorable
currency developments. Business performance by the Consumer Health Division is
weaker than previously expected.

Against this background, Bayer will be adjusting its full-year forecasts for
sales and earnings in the Crop Science and Consumer Health divisions. This will
also result in adjustments to the forecasts for Group sales and earnings
indicators.

By contrast, the Pharmaceuticals Division and Covestro continue to perform
strongly. The Animal Health business unit is performing in line with
expectations.

The outlook will be adjusted during preparation of the interim report for the
second quarter and announced with its publication.


Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields
of health care and agriculture. Its products and services are designed to
benefit people and improve their quality of life. At the same time, the Group
aims to create value through innovation, growth and high earning power. Bayer
is committed to the principles of sustainable development and to its social and
ethical responsibilities as a corporate citizen. In fiscal 2016, the Group
employed around 115,200 people and had sales of EUR 46.8 billion. Capital
expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion.
These figures include those for the high-tech polymers business, which was
floated on the stock market as an independent company named Covestro on October
6, 2015. For more information, go to www.bayer.com.


Forward-looking statements

This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer management. Various known and unknown
risks, uncertainties and other factors could lead to material differences
between the actual future results, financial situation, development or
performance of the company and the estimates given here. These factors include
those discussed in Bayer's public reports which are available on the Bayer
website at www.bayer.com. The company assumes no liability whatsoever to update
these forward-looking statements or to conform them to future events or
developments.